Jayne Gershkowitz | Chief Patient Advocate
Amicus Therapeutics

Jayne Gershkowitz, Chief Patient Advocate, Amicus Therapeutics

Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Senior Vice President and Chief Patient Advocate. She is a long-time patient advocacy professional with expertise in the rare disease community, specifically in the LSD space. Prior to joining Amicus, Ms. Gershkowitz served as Executive Director at the NTSAD Association, where she co-founded the LSD Research Consortium in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and established the NTSAD Research Initiative. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.
Ms. Gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena. She is a Co-founder and Chair of the Patient Advocacy Committee of BioNJ, and Vice President of Education of the Board of Directors of the NTSAD Association. She is currently a member of the Steering Committee of the Healthcare Institute of New Jersey; the Patient Advocacy and Access and Reimbursement Committees of the Corporate Alliance of the Global Genes RARE Project; and the Policy Working Group of the National Organization for Rare Disorders Corporate Council. Ms. Gershkowitz earned a degree in journalism from the the Newhouse School of Public Communications at Syracuse University and studied business administration at the Radcliffe Graduate Seminars Program.


World Orphan Drug Congress USA 2018 - Conference Day One @ 14:34

ROUNDTABLE 4: Expanded access - incorporating the patient advocacy perspective to develop a review process and a formalized procedure on expanded access

back to speakers